Drug intelligence / Profile preview

ENT-AD

Development stage: Preclinical
Lead developer: Metabolics Pharma
Modality: Small Molecules
Administration: Oral, Parenteral

Overview

ENT-AD is a preclinical-stage, centrally acting small molecule under development by Metabolics Pharma for the treatment of Alzheimer's disease. The drug is designed to target and inhibit Protein Tyrosine Phosphatase 1B (PTP1B), an enzyme that plays a key role in regulating insulin and leptin signaling pathways. By inhibiting PTP1B, ENT-AD aims to reverse central insulin resistance in the brain, which is increasingly recognized as a contributing factor to the cognitive decline and neurodegeneration associated with Alzheimer's disease. ENT-AD is being developed for both injectable and oral administration.

Targets

PTPN1 (Protein tyrosine phosphatase 1B)

Beyond the preview

Go deeper on ENT-AD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENT-AD.

Explore the full profile